



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: Michael Radomsky

Attorney Docket No.: DEPYP003D1C1

Application No.: 10/796,441

Examiner: Michael C. Henry

Filed: March 8, 2004

Group: 1623

Title: METHOD OF PROMOTING BONE
GROWTH WITH HYALURONIC ACID AND
GROWTH FACTORS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first-class mail on February 13, 2007 in an envelope addressed to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Signed: _____

Valerie Olsen

**INFORMATION DISCLOSURE STATEMENT
BEFORE FINAL ACTION OR NOTICE OF ALLOWANCE**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The undersigned hereby states pursuant to 37 CFR §1.97(e), that each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application. Only a copy of the relevant communication is enclosed. Because the listed references were cited in the counterpart foreign application, Applicant submits that copies need not be provided. However, if the examiner is unable to locate copies of the cited references, Applicant, upon request, will provide copies for the examiner.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this reference indeed constitutes prior art.

02/21/2007 HDESTA1 00000007 10796441

01 FC:1806

180.00 DP

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits, or after three months of the filing date of this application, whichever event occurred last, but it is believed before the mailing date of either: (i) a final action under §1.113 or (ii) a notice of allowance under §1.311, whichever occurs first.

Accompanying this Information Disclosure Statement is


- ☐ a statement as specified in 37 CFR 1.97(e); or
☒ the fee set forth in 37 CFR 1.17(p).

The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application no more than three months prior to the filing of the Information Disclosure Statement.


Enclosed is our Check No. 13219 for \$180.00 in payment of the Information Disclosure Statement Fee. If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. DEPYP003D1C1).

Dated: February 13, 2007

Respectfully submitted,
BEYER WEAVER LLP


Reginald J. Suyat
Registration No. 28,172

P.O. Box 70250
Oakland, CA 94612-0250



Form 1449 (Modified) 3rd Supplemental Information Disclosure Statement By Applicant (Use Several Sheets if Necessary)	Atty Docket No. DEYP003D1C1	Application No.: 10/796,441
	Applicant: Michael Radomsky	Filing Date March 8, 2004

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
	A54	5,079,236	01/07/92	Drizen et al.			
	A55	5,925,626	07/20/99	Della Valle et al.			
	A56						
	A57						
	A58						
	A59						

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	B6	WO 99/01143	01/14/99	PCT				
	B7	WO 98/43664	10/08/98	PCT				
	B8	WO 98/34655	08/13/98	PCT				
	B9	WO 98/14222	04/09/98	PCT				
	B10	WO 97/32591	09/12/97	PCT				

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	C45	Supplementary Partial European Search Report dated February 10, 2006, for related European Application No. EP 00 95 0736.
	C46	
	C47	
	C48	
	C49	
	C50	
Examiner		Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.